Oxaliplatin, UFT and oral leucovorin combination chemotherapy in 5-fluorouracil refractory colorectal carcinoma: A phase II study

3774 Background: This phase II study evaluated the efficacy and safety of a combination of oxaliplatin and UFT/oral leucovorin in Korean Patients with advanced colorectal cancer (ACC) previously treated with a fluorouracil-based regimen. Methods: From December 1998 to December 2001, 28 patients [male : female 12:16, median age 61 (range 37–71)] with measurable disease and Easter Cooperative Oncolgy Group performance status of 0–2 were treated with a combination of oxaliplatin (130 mg/m2 i.v. for 2 hours) on day 1, UFT (300 mg/m2 p.o.) and 5-FU (20mg/m2 p.o.) on day 1–21, every 3 weeks. Results: 10 out of 28 evaluable patients achieved complete (n=3) or partial (n=7) response, leading to an overall response rate of 35.7%. The estimated median time to progression and survival were 5.5 months and 8.5 months respectively. From the 129 cycles analyzed, sensory neuropathy was the most common toxicity (73%), grade 3,4 hematologic toxicities included neutropenia 1.5%, and thrombocytopenia 1.5%, other toxicities w...